Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fam-trastuzumab-deruxtecan + osimertinib
- Development stage
- Preclinical
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy consisting of fam-trastuzumab-deruxtecan (an antibody-drug conjugate targeting HER2) and osimertinib (a third-generation EGFR tyrosine kinase inhibitor). The combination is being investigated for the treatment of non-small cell lung cancer (NSCLC) with acquired resistance to EGFR-targeted therapies, particularly in cases where HER2 mutations or amplifications are identified as mechanisms of resistance. Fam-trastuzumab-deruxtecan delivers a cytotoxic payload specifically to HER2-expressing tumor cells, while osimertinib inhibits mutant EGFR signaling. The combination aims to overcome resistance by dual blockade of both pathways[1][3].
- Brand names
- EnhertuTagrisso
- Other names
- fam-trastuzumab deruxtecan-nxki + osimertinibtrastuzumab deruxtecan + osimertinib
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on fam-trastuzumab-deruxtecan + osimertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fam-trastuzumab-deruxtecan + osimertinib.